Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Banerji U. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37

DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.

Gilmore E. et al, (2019), J Oncol, 2019

Heterogeneity in myeloproliferative neoplasms: Causes and consequences.

O'Sullivan J. and Mead AJ., (2019), Adv Biol Regul, 71, 55 - 68

Inhibition of thymidylate synthase by the ProTide NUC-3373: in vitro analysis and clinical validation

Blagden SP. et al, (2019), MOLECULAR CANCER THERAPEUTICS, 18

NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.

Evans TRJ. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37

OVPSYCH2: A randomised study of psychological support following chemotherapy for ovarian cancer

Howells L. et al, (2019), PSYCHO-ONCOLOGY, 28, 6 - 6

Single-cell analyses reveal aberrant pathways for megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets

Psaila B. et al, (2019)

Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation

Wilkinson RDA. et al, (2019)

First-in-human Phase 1 study of f the bromondomain and extra-terminal motif inhibitor BAY 1238097: Emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

Postel-Vinay S. et al, (2018), European Journal of Cancer

Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer

Blagden SP. et al, (2018), Clinical Cancer Research, clincanres.2277.2018 - clincanres.2277.2018

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

Humphries MP. et al, (2018), Journal of Oncology, 2018, 1 - 14

Alpelisib (BYL719) Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type ER+ Advanced Breast Cancer

Juric D. et al, (2018), JAMA Oncology

From Pioneer to Repressor: Bimodal foxd3 Activity Dynamically Remodels Neural Crest Regulatory Landscape In Vivo.

Lukoseviciute M. et al, (2018), Dev Cell, 47, 608 - 628.e6

Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus > 80 Years and Idi Independently Predicts Survival

Eyre TA. et al, (2018), BLOOD, 132

Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer.

Lyon PC. et al, (2018), Radiol Case Rep, 13, 1259 - 1266

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiaze-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Replased/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Collins GP. et al, (2018), BLOOD, 132

Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Crosswell HE. et al, (2018), BLOOD, 132

CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement

Eyre TA. et al, (2018), BLOOD, 132

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

O'Sullivan J. et al, (2018), BLOOD, 132

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Korn C. et al, (2018), BLOOD, 132